Longhorn Life Sciences Inc.

One in eight surgeries results in a surgical site infection (SSI), costing the U.S. healthcare system $10 billion annually—up to 55% of which are preventable with earlier detection. Currently, there is no way to detect infection at home. Clinicians rely entirely on patients to self-report symptoms, leading to delayed treatment and costly readmissions averaging $21,000 each. Longhorn Life Sciences is developing iDetect, a wearable wound monitoring system that continuously samples wound fluid and uses machine learning to predict infection before symptoms appear. By providing clinicians with real-time early-warning alerts, iDetect enables proactive interventions that improve patient outcomes while reducing healthcare costs.

LLS has conducted 150+ customer discovery interviews with surgeons, nurses, patients, and hospital purchasing agents, validating both our value proposition and go-to-market strategy. In 2025, we demonstrated iDetect's proof of concept with 100% infection detection accuracy in human tissue wound models, capturing infection signatures within 18 hours. LLS has filed two patents with the University of Texas at Austin and secured a NASA IP license for our core sensor technology, along with DoD partnership commitments for dual-use military applications.